Breaks Categories: News

WednesdayMar 30, 2022 12:59 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is taken with an oral antidepressant and is the first FDA-approved esketamine nasal spray for adults with treatment-resistant depression (“TRD”) or to treat depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. Patients interested in the treatment option will first undergo…

Continue Reading

TuesdayMar 29, 2022 12:15 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Significant Milestone Toward Advancing CYB003 Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the completion of in vivo preclinical studies evaluating its deuterated psilocybin analog CYB003 for the potential treatment of major depressive disorder (“MDD”). According to the update, data from the studies demonstrate that CYB003 is well-tolerated following several doses in multiple species and support the advancement toward an investigational new drug (“IND”) filing with the U.S. Food and Drug Administration (“FDA”) for a Phase 1/2a first-in-human clinical trial in patients with MDD. “The completion of these in vivo preclinical studies for CYB003 represents a…

Continue Reading

FridayMar 25, 2022 10:58 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Subsidiary Achieves Milestone Outlined in Contribution Agreement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved a key milestone. The milestones were identified in the Dec. 4, 2020, contribution agreement between Cybin and Adelia and include Year 1 Q4 (vi), Year 2 Q2 (ii), Year 2 Q2 (v) and Year 2, Q3 (iii). Others involved in the agreement include Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. According to the agreement, Adelia shareholders will be issued 90,546.0 Class B shares in Cybin; those shares are exchangeable…

Continue Reading

ThursdayMar 24, 2022 2:12 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Commences Participant Recruitment in Feasibility Study Using Kernel Flow Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its company-sponsored feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow, is actively recruiting participants. The study will evaluate participants’ experience wearing Kernel Flow while in an altered state of consciousness following the administration of ketamine. “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” Cybin’s Chief Executive Officer Doug Drysdale said in the press release. “Until now, our understanding of the psychedelic experience has been fairly subjective.…

Continue Reading

ThursdayMar 24, 2022 1:42 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces IRB Approval for Planned Smoking Cessation Study

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has received conditional approval from the Institutional Review Board ("IRB") for its planned multisite phase 2b smoking cessation trial. According to the announcement, Johns Hopkins University will serve as the lead investigational site for the study. The company anticipates submitting its IND application in the second quarter, with hopes that the study will begin shortly thereafter. Calling the approval a “significant milestone,” the company noted that its mission is to provide safer, more effective solutions to address nicotine dependence…

Continue Reading

WednesdayMar 23, 2022 1:55 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Participating, Presenting at Upcoming Investor Conferences

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be represented at three upcoming events: the Scottsdale Capital Event, Planet MicroCap Showcase and H.C. Wainwright Annual Global Life Sciences Conference. Delic CEO and cofounder Matt Stang will present at each event, including providing an outline of the company’s strategic outlook; he  will also be available for one-on-one meetings at each event. Hosted by Capital Event Management, the Scottsdale Capital Event is scheduled for April 22–24, 2022. This event is designed to connect growing companies with premier financiers through meetings and…

Continue Reading

ThursdayMar 17, 2022 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO, Cofounder Featured on the Jesse Tee Show Interview

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and company CEO and cofounder Matt Stang were spotlighted during a recent segment of the Jesse Tee Show. During the interview, Stang provided a summary of the journey to his present position with Delic Holdings, noting that he started as an intern with “High Times.” He worked in several positions at the publication, eventually buying out one of the owners. Stang also discussed the therapeutic potential of psychedelic compounds and provided a brief history of Delic. “In 2016, we put ‘High Times’ up…

Continue Reading

WednesdayMar 16, 2022 11:30 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Footprint with Opening of Reno Clinic

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its presence within the state of Nevada with the opening of its Reno location. According to the announcement, KWC Reno is the second of the company's clinics to open in Nevada within the last 18 months, bringing the total number of KWC clinics to 13 across nine states. The 2,200-square-foot treatment facility will serve local patients while also opening its doors to patients in larger California markets who do not have access to affordable in-state providers. “With…

Continue Reading

WednesdayMar 16, 2022 11:22 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Upcoming Maxim Group Virtual Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM) is planning to participate in the 2022 Virtual Growth Conference. The conference is slated for March 28–30, 2022, from 9 a.m. to 5 p.m. ET. Cybin CEO Doug Drysdale will present at the premier event, which is presented by Maxim Group LLC and hosted by M-Vest. Drysdale’s presentation will be available on demand at 9 a.m. ET on Monday, March 28. An archived version of Drysdale’s webcast will be available on the Company’s investor relations website. To view Drysdale’s presentation, visit https://ibn.fm/b928V To view the full press…

Continue Reading

ThursdayMar 10, 2022 12:54 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ March Conference to Showcase Curated CEOs, Capital Advisors and Investment Luminaries from Around the World

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: March 2022 Conference. The event, slated to take place in an entirely virtual format on Thursday March 24, will feature some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly conference series that dives deep into psychedelic medicine investment, the event will introduce investors and attendees to a carefully selected group of CEOs, capital advisors and luminaries from around the world. “Over the last 18 months of hosting the Psychedelic…

Continue Reading